Quidel Corp
F:QL1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Q
|
Quidel Corp
F:QL1
|
US |
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
C
|
China Resources Land Ltd
OTC:CRBJY
|
HK |
|
A
|
Align Technology Inc
XBER:AFW
|
US |
|
I
|
Intel Corp
SWB:INL
|
US |
|
P
|
Perusahaan Gas Negara Tbk PT
OTC:PPAAY
|
ID |
|
N
|
Norfolk Southern Corp
XBER:NFS
|
US |
Quidel Corp
Quidel Corp makes diagnostic tests and testing systems used to find diseases and conditions quickly. Its products include rapid point-of-care tests, lab-based assays, and the instruments that read those tests. The company focuses on areas such as infectious disease, women’s health, and heart-related testing, where doctors need fast and reliable answers. Its main customers are hospitals, clinics, physician offices, laboratories, and public health groups. Quidel sells test kits, cartridges, analyzers, and related supplies, and it also earns money from service and recurring consumable sales after a customer installs its equipment. That makes the business part equipment provider and part repeat-purchase consumables business. What sets Quidel apart is its role in the testing chain: it helps move diagnosis closer to the patient instead of sending every sample to a central lab. That makes its products useful in places where speed matters and where doctors need to make treatment decisions right away.
Quidel Corp makes diagnostic tests and testing systems used to find diseases and conditions quickly. Its products include rapid point-of-care tests, lab-based assays, and the instruments that read those tests. The company focuses on areas such as infectious disease, women’s health, and heart-related testing, where doctors need fast and reliable answers.
Its main customers are hospitals, clinics, physician offices, laboratories, and public health groups. Quidel sells test kits, cartridges, analyzers, and related supplies, and it also earns money from service and recurring consumable sales after a customer installs its equipment. That makes the business part equipment provider and part repeat-purchase consumables business.
What sets Quidel apart is its role in the testing chain: it helps move diagnosis closer to the patient instead of sending every sample to a central lab. That makes its products useful in places where speed matters and where doctors need to make treatment decisions right away.
Q1 hit: Total revenue was $620 million, but results were pressured by a much weaker respiratory season and slower sales in China ahead of expected pricing changes.
Outlook cut: Management lowered 2026 revenue guidance to $2.7 billion to $2.75 billion and now expects adjusted EBITDA of $615 million to $630 million.
Cash flow: Q1 free cash flow was negative $67 million, but the company still expects full-year free cash flow of $100 million to $120 million.
China risk: China remains a headwind, but management said it does not plan to exit the market and believes the business will stay accretive to margins.
Growth drivers: The company highlighted LEX Diagnostics, the high-sensitivity troponin assay, and the VITROS 450 rollout as key longer-term growth supports.
